This database contains 1433 studies, archived under the term: ""
Click here to filter this large number of results.
Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years
Stoeck, K.,
Sanchez-Juan, P.,
Gawinecka, J.,
Green, A.,
Ladogana, A.,
Pocchiari, M.,
Sanchez-Valle, R.,
Mitrova, E.,
Sklaviadis, T.,
Kulczycki, J.,
Slivarichova, D.,
Saiz, A.,
Calero, M.,
Knight, R.,
Aguzzi, A.,
Laplanche, J.-L.,
Peoc'h, K.,
Schelzke, G.,
Karch, A.,
van Duijn, C. M.,
Zerr, I.
To date, cerebrospinal fluid analysis, particularly protein 14-3-3 testing, presents an important approach in the identification of Creutzfeldt-Jakob disease cases. However, one special point of criticism of 14-3-3 testing is the specificity in the differential diagnosis of rapid dementia. The constant observation of increased cerebrospinal fluid referrals in the national surveillance centres over the last […]
ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients
Steinacker, Petra,
Klafki, Hans,
Lehnert, Stefan,
Jesse, Sarah,
Arnim, Christine A. F. V.,
Tumani, Hayrettin,
Pabst, Alice,
Kretzschmar, Hans A.,
Wiltfang, Jens,
Otto, Markus
The clinical diagnosis of Creutzfeldt-Jakob disease (CJD) can be supported by several biochemical markers in cerebrospinal fluid (CSF) such as 14-3-3 proteins and tau protein. Unfortunately, none of the currently known markers are suited for screening or seems to be directly related to the pathophysiological process. A marker fulfilling these criteria might facilitate the early […]
The Peaceful Mind program: A pilot test of a cognitive–behavioral therapy–based intervention for anxious patients with Dementia
Stanley, Melinda A.,
Calleo, Jessica,
Bush, Amber L.,
Wilson, Nancy,
Snow, A. Lynn,
Kraus-Schuman, Cynthia,
Paukert, Amber L.,
Petersen, Nancy J.,
Brenes, Gretchen A.,
Schulz, Paul E.,
Williams, Susan P.,
Kunik, Mark E.
Objectives: To assess feasibility and to conduct a preliminary evaluation of outcomes following Peaceful Mind, a cognitive-behavioral therapy-based intervention for anxiety in dementia, relative to usual care. Design: Pilot randomized controlled trial including assessments at baseline and 3 and 6 months. Setting: Houston, TX. Participants: Thirty-two outpatients diagnosed with mild (47%) or moderate (53%) dementia […]
The peaceful mind program: a pilot test of a cognitive-behavioral therapy-based intervention for anxious patients with dementia
Stanley, Melinda A.,
Calleo, Jessica,
Bush, Amber L.,
Wilson, Nancy,
Snow, A. Lynn,
Kraus-Schuman, Cynthia,
Paukert, Amber L.,
Petersen, Nancy J.,
Brenes, Gretchen A.,
Schulz, Paul E.,
Williams, Susan P.,
Kunik, Mark E.
Objectives: To assess feasibility and to conduct a preliminary evaluation of outcomes following Peaceful Mind, a cognitive-behavioral therapy-based intervention for anxiety in dementia, relative to usual care.; Design: Pilot randomized controlled trial including assessments at baseline and 3 and 6 months.; Setting: Houston, TX.; Participants: Thirty-two outpatients diagnosed with mild (47%) or moderate (53%) dementia […]
Effects of a low-volume, nutrient- and energy-dense oral nutritional supplement on nutritional and functional status: a randomized, controlled trial in nursing home residents
Stange, Inken,
Bartram, Matthias,
Liao, Yuye,
Poeschl, Karin,
Kolpatzik, Sarah,
Uter, Wolfgang,
Sieber, Cornel C.,
Stehle, Peter,
Volkert, Dorothee
Objectives: Although oral nutritional supplements (ONS) are known to be effective to treat malnutrition in the elderly, evidence from nursing home populations, including individuals with dementia, is rare, especially with regard to functionality and well-being. A known barrier for ONS use among elderly is the volume that needs to be consumed, resulting in low compliance […]
One-year safety and tolerability profile of pridopidine in patients with Huntington disease
Squitieri, Ferdinando,
Landwehrmeyer, Bernhard,
Reilmann, Ralf,
Rosser, Anne,
de Yebenes, Justo Garcia,
Prang, Allan,
Ivkovic, Jelena,
Bright, Jeremy,
Rembratt, Åsa
Objective: To assess the 1-year safety profile of the dopaminergic stabilizer pridopidine in patients with Huntington disease. Methods: Patients received pridopidine 45 mg/day for 4 weeks then pridopidine 90 mg/day for 22 weeks in this 6-month open-label extension (OLE) of the 6-month MermaiHD randomized controlled trial (RCT). Any adverse events (AEs) were recorded. Patients were […]